|
WO2020231909A1
|
|
Compositions and methods for treating bile acid associated diseases
|
|
WO2020214879A1
|
|
Sustained release formulations
|
|
US2020163952A1
|
|
Compositions and methods for treating nerve agent exposure
|
|
EP3612225A1
|
|
Compositions and methods for treating retinopathy
|
|
AU2017322332A1
|
|
Compositions for treating dementia
|
|
US2019022224A1
|
|
Compositions and methods for treating stress-related disorders
|
|
US2017181993A1
|
|
Methods of Treating Amyotrophic Lateral Sclerosis and Symptoms
|
|
AU2016247301A1
|
|
Compositions and methods for treating autism
|
|
US2016199453A1
|
|
Transdermal formulations
|
|
US2016193169A1
|
|
Compositions and methods for treating intestinal hyperpermeability
|
|
KR20170117390A
|
|
Transdermal formulations
|
|
US2015111937A1
|
|
Compositions and methods for treating intestinal hyperpermeability
|
|
US2015111878A1
|
|
Compositions and methods for treating intestinal hyperpermeability
|
|
US2013183263A1
|
|
Pharmaceutical compositions and methods
|
|
US8481498B1
|
|
Pharmaceutical compositions and methods
|
